MIRM Q2 2023 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M+114.5% YoY

Gross Profit

$31M81.8% margin

Operating Income

-$24M-64.7% margin

Net Income

-$74M-197.5% margin

EPS (Diluted)

$-1.94

QoQ Revenue Growth

+18.7%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$444M

Total Liabilities

$365M

Stockholders' Equity

$79M

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$17M	+114.5%
Gross Profit	$31M	$15M	+105.1%
Operating Income	-$24M	-$31M	+22.8%
Net Income	-$74M	-$27M	-175.0%

Revenue Segments

Product

$32M87%

License

$5M13%